Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with multiple myeloma (a type of blood cancer) according to international diagnostic standards, with signs of the disease that can be measured by a central laboratory at the time of screening
- People who have already received between 1 and 3 previous treatments for their multiple myeloma, including a specific type of drug that targets a protein called CD38, and a drug called lenalidomide
- People whose overall physical health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (called the ECOG scale, scored 0 to 2) at the time of screening and just before starting the study treatment
- People whose blood and lab test results meet specific levels set out in the study rules, checked during screening and within 1 day of starting the study treatment
Who may not be able to join:
- People who have had major surgery (for example, surgery requiring general anaesthesia) or a serious physical injury within 2 weeks before the first dose, who have not fully recovered from surgery, or who have surgery planned during the expected period of study participation
- People who are known or suspected to have allergies, sensitivities, intolerances, or other medical reasons that would make it unsafe to take the study drugs (JNJ-79635322 or teclistamab) or their ingredients
- People who have any ongoing blood or bone marrow conditions other than multiple myeloma, a history of another cancer that is considered at high risk of returning and may need ongoing treatment, or another active cancer (meaning one that has been progressing or required a treatment change within the last 24 months)
- People who have known or suspected involvement of multiple myeloma in the brain or spinal fluid, or who show clinical signs of this — unless specific brain scans and fluid tests come back negative (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Complete Response (CR) or Better; Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.